Education
About Us
Working with TipRanks
Follow Us
Optinose Inc (OPTN)
NASDAQ:OPTN
OPTN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.82 - $21.15
Previous CloseN/A
Volume6.27K
Average Volume (3M)124.48K
Market Cap
$92.64M
Enterprise Value$122.20M
Total Cash (Recent Filing)$84.48M
Total Debt (Recent Filing)$128.96M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
May 08, 2025EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.93
Shares Outstanding10,124,281
10 Day Avg. Volume335,189
30 Day Avg. Volume124,478
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.22
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.72
Enterprise Value/Ebitda-103.04
Forecast
1Y Price Target
$9.00Price Target Upside-1.75% Downside
Rating ConsensusHold
Number of Analyst Covering3
---
Optinose News
PremiumCompany Announcements
Optinose Reports Revenue Growth Amid Financial Challenges
---
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactOptiNose's acquisition by Paratek Pharmaceuticals presents an opportunity to broaden the commercial reach of XHANCE by targeting not only ENTs and allergy specialists, but also primary care providers.
Market ExpansionThe March 15, 2024 approval of an sNDA expands the addressable market by 3x and alleviates payer challenges.
Bears Say
Financial Outlook AdjustmentThe rating for OptiNose has been changed to Neutral and the price target reduced, reflecting adjustments in light of the announced acquisition.
Price Target ReductionThe rating is being lowered to Hold and the price target to $9 from $17.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OPTN FAQ
What was Optinose Inc’s price range in the past 12 months?
Optinose Inc lowest stock price was $4.82 and its highest was $21.15 in the past 12 months.
What is Optinose Inc’s market cap?
Optinose Inc’s market cap is $92.64M.
When is Optinose Inc’s upcoming earnings report date?
Optinose Inc’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Optinose Inc’s earnings last quarter?
Optinose Inc released its earnings results on Mar 26, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.607 by $0.577.
Is Optinose Inc overvalued?
According to Wall Street analysts Optinose Inc’s price is currently Overvalued.
Does Optinose Inc pay dividends?
Optinose Inc does not currently pay dividends.
What is Optinose Inc’s EPS estimate?
Optinose Inc’s EPS estimate is -0.74.
How many shares outstanding does Optinose Inc have?
Optinose Inc has 10,124,281 shares outstanding.
What happened to Optinose Inc’s price movement after its last earnings report?
Optinose Inc reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.607. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Optinose Inc?
Currently, no hedge funds are holding shares in OPTN
---
Optinose Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.00 (-1.75% Downside)
$9.00 (-1.75% Downside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.69%
12-Months-Change
Fundamentals
Return on Equity
75.79%
Trailing 12-Months
Asset Growth
19.55%
Trailing 12-Months
Company Description
Optinose Inc
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
---
OPTN Company Deck
---
OPTN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture. While there are positive trends in prescription growth and revenue per prescription, the overall financial performance did not meet expectations, resulting in a downward revision of revenue guidance. There are also operational challenges in prescription fulfillment and prior authorization requirements.Read More>---
OPTN Stock 12 Month Forecast
Average Price Target
$9.00
▼(-1.75% Downside)
Technical Analysis
Galectin Therapeutics
―
XBiotech
―
Renovaro Biosciences
―
Black Diamond Therapeutics
―
Vor Biopharma
―
Best Analysts Covering OPTN
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-47.28%
reiterated a buy rating 3 months ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -47.28% per trade.
---